Dynor Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 28 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.20 M
- Revenue Growth -16.44%
- Profit Growth -18.99%
- Ebitda -12.39%
- Net Worth 4.74%
- Total Assets 1.11%
About Dynor Pharmaceuticals
Dynor Pharmaceuticals Private Limited (DPPL) is a Private Limited Indian Non-Government Company incorporated in India on 18 March 1996 and has a history of 28 years and ten months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹1.20 M.
Bharat Tuteja and Manik Tuteja serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24231DL1996PTC077290
-
Company No.
077290
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
18 Mar 1996
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Dynor Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bharat Tuteja
|
Managing Director | 18-Mar-1996 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Manik Tuteja
|
Director | 20-Oct-2022 | Current |
Financial Performance of Dynor Pharmaceuticals.
Dynor Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 16.44% decrease. The company also saw a substantial fall in profitability, with a 18.99% decrease in profit. The company's net worth moved up by a moderate rise of 4.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dynor Pharmaceuticals?
In 2020, Dynor Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.20 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.12 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 May 2009 | State Bank Of India | ₹1.20 M | Open |
How Many Employees Work at Dynor Pharmaceuticals?
Unlock and access historical data on people associated with Dynor Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dynor Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dynor Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
